Caris Life Sciences to Present Groundbreaking Research at ESMO 2024
![Caris Life Sciences to Present Groundbreaking Research at ESMO 2024](https://investorshangout.com/images/blog/ihnews-Caris%20Life%20Sciences%20to%20Present%20Groundbreaking%20Research%20at%20ESMO%202024.jpg)
Caris Life Sciences to Present Groundbreaking Research at ESMO 2024
In collaboration with leading cancer centers, Caris Life Sciences (Caris) is set to showcase key research findings that underline the clinical value of comprehensive molecular profiling at the European Society for Medical Oncology (ESMO) Congress 2024. With seven studies to be presented, the research spans a wide range of tumor types, showcasing Caris' impact on precision medicine.
Insightful Research Across Diverse Cancer Types
Caris and its collaborators from the biopharma industry and esteemed cancer centers will present their findings at Booth #608 during ESMO 2024. These findings highlight the significant power of Caris' comprehensive multi-modal database, which enables innovative insights into cancer that can profoundly influence a patient's diagnosis, prognosis, care plan, and treatment responses.
Commitment to Precision Oncology
Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD, stated that the research showcased at the ESMO Congress exemplifies Caris' dedication to data-driven molecular innovation. He emphasized how the expanding collaborative network is tackling some of the most pressing questions in precision oncology today.
Transformative Findings in Cancer Care
Sledge continued, "The findings underscore the critical role of comprehensive profiling in cancer care and the potential of large clinico-genomic datasets.
Our extensive sequencing and data analysis efforts are unlocking new pathways for tailored therapies that could revolutionize cancer treatment." Through such initiatives, Caris is paving the way for improved patient outcomes and more personalized treatment options.
Highlighted Presentations from ESMO 2024
This year, Caris will feature notable findings in both mini oral presentations and poster sessions:
Mini Oral Presentations
- Metastatic hormone receptor-positive breast cancer outcomes: This study analyzed 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants to understand the intersection of genomics and targeted therapy sequencing. (Abstract Number: 342MO)
- Atlas of tertiary lymphoid structures in solid tumors: This research focuses on genomic characteristics and how they predict response to immunotherapy. (Abstract Number: 75MO)
Poster Presentations
- Impact of TLS Status: An exploration of outcomes in patients with high tumor mutational burden (TMB) or microsatellite instability-high (MSI-H) status receiving immune checkpoint inhibitors. (Abstract Number: 1051P)
- Comparison of HER2 Immunohistochemistry Scoring: This presentation analyzes scoring criteria used in assessing endometrial endometrioid adenocarcinoma (EEA). (Abstract Number: 739P)
- Evaluating c-Met Protein Overexpression: The METPRO study assesses the prognostic value of c-Met protein presence and concurrent biomarker evaluation. (Abstract Number: 1303P)
- HER2 Low-Expressing Tumors: The genomic landscape and prognostic impacts of HER2 low-expressing tumors will be discussed. (Abstract Number: 126P)
- Prostate Cancer Insights: Investigating high PSMA/FOLH1 mRNA expression in prostate cancer and its relevance. (Abstract Number: 1653P)
Caris Precision Oncology Alliance
The Caris Precision Oncology Alliance (POA) comprises 95 cancer centers, including 46 NCI-designated cancer centers. This collaboration aims to further precision oncology and foster biomarker-driven research for improving patient outcomes.
In unison, Caris and POA members are committed to establishing and optimizing molecular care standards that focus on predictive and prognostic markers.
About Caris Life Sciences
Caris Life Sciences is a pioneering next-generation AI TechBio company at the forefront of precision medicine. The company is dedicated to transforming healthcare through innovative solutions and comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing. By applying advanced AI and machine learning algorithms to a vast array of data, Caris has developed powerful tools for early detection, diagnosis, treatment selection, and drug development.
Founded with the aspiration to fully realize precision medicine’s potential, Caris prioritizes both its employees and patients from all backgrounds. With headquarters in Texas and offices around the world, Caris collaborates globally to provide vital services that improve healthcare outcomes in diverse populations.
Contact Information
For media inquiries, please contact:
Corporate Communications
Email: info@carislifesciences.com
Phone: 214.294.5606
Frequently Asked Questions
What is Caris Life Sciences best known for?
Caris Life Sciences is renowned for its innovative approach in precision medicine, utilizing advanced technology to provide comprehensive molecular profiling for cancer treatment.
What are the key findings presented by Caris at ESMO 2024?
At ESMO 2024, Caris will present findings from seven studies that emphasize the role of their multi-modal database in enhancing cancer diagnosis and treatment strategies.
What is the Caris Precision Oncology Alliance?
The Caris POA is a collaborative network of cancer centers and academic institutions dedicated to advancing precision oncology research and ensuring optimal standards of care for cancer patients.
How does Caris contribute to cancer research?
Caris contributes to cancer research by combining comprehensive molecular profiling with rich clinical data, helping clinicians and researchers discover new biomarkers that can lead to better treatment outcomes.
How can I learn more about Caris Life Sciences?
To learn more about Caris Life Sciences and their innovative solutions, you can visit their official website or contact their communications team for more information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- KommuneKredit Reports Impressive H1 2024 Financial Results
- Survey Highlights Employee Relations as Business Complexity Factor
- Service World Expo 2024: Key Insights and Exciting Trends
- Critical Metals Corp. Launches Drilling at Tanbreez Project
- Cadar Appoints Ralph Simons as CEO to Lead Fine Jewelry Brand
- Guidehouse Welcomes Patrick Spoletini as Growth Leader in Health
- NKF Launches Essential Online Education for Kidney Disease
- Acer Unveils Swift Go 14 AI and Swift 14 AI Laptops Boosting Productivity
- Flexential's Innovative Growth Strategies Set for 2024 Success
- Cetaphil Unveils Gentle Exfoliating Line Featuring Katie Fang
- Market Volatility: Recession Fears Impact Investor Confidence
- Acer Unveils TravelMate P6 14 AI: A Game Changer in Laptops
- Critical Metals Launches Major Drilling Program at Tanbreez
- Saudi Arabia's Stock Market Overview: Tadawul Performance Insights
- Ongoing Ozempic Shortages Impacting Europe into Q4 2024
- Stocks Remain Resilient Amid Market Volatility: Insights
- Wells Fargo Expands 'Signature Picks' with Microsoft and Adobe
- SSI Raises $1 Billion to Develop Advanced AI Safety Solutions
- Global Market Index Sees Declining Returns for Investors
- Catchlight Launches Beta for Innovative Lead Routing Model
- Montway Auto Transport Celebrated as 2024 MOTOR Top 20 Winner
- GOOD GOOD Launches Innovative No Added Sugar Vegan Lemon Curd
- Solid Waste Management Market Expected to Hit $440 Billion by 2032
- Automated Liquid Handling Technologies Set for Major Growth
- The Dermatology Specialists Launch 50th Location with Free Screenings
Recent Articles
- Vaseline® Launches Pro Vitab3 Serum-Burst Lotion for Skin Care
- Survey Highlights Employee Relations as Business Complexity Factor
- Service World Expo 2024: Key Insights and Exciting Trends
- Acer Unveils TravelMate P6 14 AI: A Game Changer in Laptops
- Automated Liquid Handling Technologies Set for Major Growth
- Cinnamon-Based Solution: A Game Changer for Wound Care
- Remitly to Showcase Innovations at Upcoming Conference
- Biomerica's At-Home PSA Test Approved in Saudi Arabia
- Net-Trade.com Celebrated as a Key Influencer in Net Lease
- Symphony Talent Unveils SFX Brand Amplifier for Recruitment
- Axcelis to Sponsor International Ion Implantation Conference 2024
- Lyft to Streamline Operations by Selling Bike and Scooter Assets
- Lumen Technologies Faces Skepticism Amid AI Investment Hype
- Intel's Collaboration with IBM Marks a New Era in AI Chips
- Psyence Biomed Partners with PsyLabs for Psilocybin Research
- Arbe Tier-1 Sensrad Secures Framework Agreement for 4D Imaging
- Berkshire Hathaway: Buffett's Vision and Future Considerations
- Hormel Foods Releases Impressive Q3 2024 Financial Results
- Conveyor System Market Set to Reach $14.8 Billion by 2030
- Man Group PLC's Recent Disclosure on International Paper Company
- Way.com Teams Up with Sea Air FCU for Affordable Auto Loans
- Zscaler's Revenue Forecast Falls Short Amid Cybersecurity Challenges
- Mr. Lid Launches New Lunch Bento Boxes for Back to School
- MidWestOne Bank Enhances Digital Onboarding Experience
- Kia America's Record August Sales & Electrified Model Growth